Put Options

15 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$253.3 - $285.89 $1.55 Million - $1.74 Million
6,100 New
6,100 $1.57 Million
Q4 2022

Feb 14, 2023

SELL
$252.44 - $306.72 $631,100 - $766,800
-2,500 Reduced 42.37%
3,400 $941,000
Q3 2022

Nov 14, 2022

SELL
$194.69 - $268.46 $4.59 Million - $6.34 Million
-23,600 Reduced 80.0%
5,900 $1.58 Million
Q2 2022

Aug 17, 2022

SELL
$187.54 - $223.02 $4.26 Million - $5.06 Million
-22,700 Reduced 43.49%
29,500 $6.02 Million
Q1 2022

May 16, 2022

BUY
$193.77 - $244.14 $5.58 Million - $7.03 Million
28,800 Added 123.08%
52,200 $11 Million
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $5.24 Million - $6.73 Million
23,400 New
23,400 $5.61 Million
Q1 2021

May 17, 2021

SELL
$242.95 - $284.63 $1.12 Million - $1.31 Million
-4,600 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$258.66 - $342.55 $310,392 - $411,060
1,200 Added 35.29%
4,600 $1.23 Million
Q1 2020

May 15, 2020

SELL
$268.85 - $341.04 $6.88 Million - $8.73 Million
-25,600 Reduced 88.28%
3,400 $1.08 Million
Q4 2019

Feb 14, 2020

BUY
$220.06 - $304.07 $2.18 Million - $3.01 Million
9,900 Added 51.83%
29,000 $8.6 Million
Q3 2019

Nov 13, 2019

BUY
$217.44 - $243.88 $3.5 Million - $3.93 Million
16,100 Added 536.67%
19,100 $4.45 Million
Q2 2019

Aug 13, 2019

SELL
$219.29 - $241.72 $614,012 - $676,816
-2,800 Reduced 48.28%
3,000 $701,000
Q1 2019

May 14, 2019

SELL
$216.71 - $338.96 $86,684 - $135,584
-400 Reduced 6.45%
5,800 $1.37 Million
Q4 2018

Feb 13, 2019

BUY
$278.5 - $352.75 $807,650 - $1.02 Million
2,900 Added 87.88%
6,200 $1.87 Million
Q2 2018

Aug 03, 2018

BUY
$257.52 - $306.91 $849,815 - $1.01 Million
3,300 New
3,300 $957,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Centiva Capital, LP Portfolio

Follow Centiva Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Centiva Capital, LP with notifications on news.